Ref (type)	Population	Outcome, Interventions	Results and statistical analysis	Effect size	Favours
Adverse effects
RCT	360 children aged 12–17 years In review	Adverse effects with rizatriptan with placebo Absolute results not reported	Significance not assessed
RCT	1382 children aged 6–17 years	Any adverse effects 106/462 (23%) with rizatriptan (dosed based on weight) 113/515 (22%) with placebo	Significance not assessed
RCT	1382 children aged 6–17 years	Serious adverse effects 0/462 (0%) with rizatriptan (dosed based on weight) 2/515 (<1%) with placebo	Significance not assessed